Talphera (NASDAQ:TLPH) Issues Earnings Results

Talphera (NASDAQ:TLPH) announced its quarterly earnings data on Thursday. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06), FiscalAI reports.

Talphera Trading Down 0.4%

Shares of NASDAQ:TLPH traded down $0.01 during trading on Friday, reaching $1.21. 226,515 shares of the stock were exchanged, compared to its average volume of 255,054. Talphera has a 12 month low of $0.40 and a 12 month high of $1.57. The firm has a market cap of $62.54 million, a PE ratio of -4.46 and a beta of 0.69. The stock has a 50-day moving average price of $1.19 and a 200-day moving average price of $0.96.

Hedge Funds Weigh In On Talphera

A number of large investors have recently made changes to their positions in TLPH. Group One Trading LLC boosted its stake in Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after purchasing an additional 29,500 shares during the period. Virtu Financial LLC bought a new position in Talphera during the 3rd quarter worth $29,000. Persistent Asset Partners Ltd bought a new position in Talphera during the 4th quarter worth $42,000. Mariner LLC lifted its holdings in shares of Talphera by 132.0% during the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after buying an additional 33,000 shares in the last quarter. Finally, Dauntless Investment Group LLC acquired a new stake in shares of Talphera during the third quarter worth $89,000. Institutional investors own 37.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on TLPH. Zacks Research upgraded shares of Talphera to a “hold” rating in a research note on Monday, June 8th. Wall Street Zen raised Talphera to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of Talphera in a research note on Thursday. Westpark Capital began coverage on Talphera in a research report on Thursday, April 30th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Talphera has a consensus rating of “Hold” and a consensus target price of $3.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.